MTOR and fatty liver disease: Also, sitagliptin, a dipeptidyl-peptidase 4 inhibitor, has been reported to exert more biological properties beyond its antidiabetic effect; in particular, it has been shown to ameliorate the development of liver steatosis by inhibiting inflammatory responses and by activating autophagy via AMPK/mTOR pathway (Zheng et al., 2018).